Key Takeaways
-
Dental practice succession planning is a sequenced risk-management process that prepares a practice financially, operationally, and legally for ownership transfer.
-
Starting the process late or without a diligence-grade, CPA-led EBITDA analysis can cost owners 15–30% of practice value and invite deal re-trading after the LOI.
-
Three primary pathways, doctor-to-doctor, DSO/private equity, and internal associate buy-in, differ in timeline, liquidity, autonomy, and post-close risk, so owners benefit from a side-by-side comparison.
-
Common failure modes include associate mobility, owner dependency, deal re-trading, and missing buy-sell triggers, especially the disability clause that is statistically the most likely to force an unplanned transition.
-
McLerran & Associates provides dental-only, sell-side guidance with a CPA-led valuation and structured buyer competition to help owners improve outcomes and avoid common transition pitfalls.
Start your succession plan with a confidential conversation.
The Dental Practice Transition Timeline: What To Do At Each Stage
Planning early usually protects more value than any single deal term. The table below maps the three planning stages against the actions required at each stage and shows how the financial consequence of inaction grows as the window narrows.
|
Stage |
Actions |
Financial Consequence |
|---|---|---|
|
5+ Years Out (Preparation) |
Get a diligence-grade, CPA-led valuation, clean up historical financials, reduce owner dependency, document systems and repeatable processes. |
|
|
3–4 Years Out (Identification) |
Identify and mentor internal associates or evaluate external buyers and DSOs, assemble a transition team of dental-specific advisors. |
|
|
1–2 Years Out (Execution) |
Formalize buy-sell agreements, secure legal and tax counsel, structure the transition timeline, and confirm buyer financing. |
The worst time to get a first valuation is after receiving a letter of intent, when there is no basis for comparison and no time to fix gaps. |
The three-stage framework above is a starting point. Actual sequencing depends on the practice’s size, specialty, ownership structure, and the owner’s personal goals. McLerran & Associates begins every engagement by clarifying the owner’s “why” before recommending any path.
See where your practice falls on the transition timeline.
Doctor-To-Doctor Vs. DSO Sale: Comparing The Three Transition Pathways
Most owner-dentists choose among three transition pathways. The table below compares them on the dimensions owners weigh most often, timeline, cash at close, autonomy, and post-close risk, and illustrates why the fastest path rarely produces the strongest economics.
|
Pathway |
Typical Timeline |
Cash At Close (% Of Total Deal Value) |
Autonomy & Risk |
|---|---|---|---|
|
Doctor-to-Doctor |
6–12 months from decision to close |
In doctor-to-doctor (private) sales, cash at closing typically runs 90% to 100% of the total price |
Preserves patient and staff culture, yet high associate turnover risk and buyer financing hurdles can derail the deal. |
|
DSO / Private Equity |
Typically 6–12+ months from listing or engagement to close, though DSO transactions specifically often run longer, commonly 8–18 months or 9–13 months, due to multi-layer due diligence and internal approval processes |
Commonly 60–85%+ of total consideration as cash at close, up to ~40% payable in rollover equity |
Higher immediate liquidity potential, with some loss of clinical autonomy and corporate oversight post-close. |
|
Internal Associate Buy-In |
Phased over multiple years |
Provides seamless patient continuity, yet remains vulnerable to associate mobility before vesting is complete. |
The mechanics behind each pathway differ. DSO pricing works off an EBITDA multiple and often includes rollover equity, meaning the seller retains a minority ownership stake in the acquiring platform, which converts to cash only at the DSO’s future recapitalization or sale, typically 3–7 years away. Doctor-to-doctor pricing often uses a percentage of revenue or a multiple of net cash flow. Internal buy-ins are structured as a partnership buy-in over time rather than a single sale event, with the associate purchasing a defined equity stake, commonly 25–50%, on a defined timeline to full ownership.
McLerran & Associates is one of the few firms that runs both private-buyer and DSO transactions in roughly equal measure, approximately a 50/50 split, so owners receive a side-by-side valuation that quantifies their worth in both markets before choosing a path.
Find out what your practice is really worth — request a comprehensive practice valuation.
What Are the 5 Steps Of Succession Planning?
Whichever pathway an owner chooses, the underlying sequence of work stays consistent. The five steps below apply to all three pathways, with only the timing and counterparty changing.
-
Get a diligence-grade, CPA-led valuation and EBITDA analysis. This baseline should hold up when buyers scrutinize it, prevent re-trading at the LOI stage, and guide every step that follows.
-
Reduce owner dependency. With a defensible valuation in hand, close the gap between what the practice is worth today and what it could be worth by diversifying production, documenting processes, and building leadership depth.
-
Choose your pathway. Once the practice can stand on its own, compare doctor-to-doctor, DSO/private equity affiliation, and internal associate buy-in using a genuine side-by-side view of economics, autonomy, and cultural fit.
-
Formalize the legal and funding structure. After selecting a path, work with legal and tax counsel to finalize the buy-sell agreement, triggering events, insurance coverage, and tax structure before going to market.
-
Create competition among vetted buyers and control the narrative around EBITDA through diligence. A structured, competitive process helps the agreed value hold at closing.
What Is The 50-40-30 Rule In Dentistry?
Overhead is one of the largest levers on a dental practice’s valuation multiple, and the 50-40-30 rule is the benchmark buyers use to judge it. Overhead should represent no more than 50% of collections for a solo practice, 40% for a small group, and 30% for a mature DSO platform.
Buyers apply the rule as a quick screen before committing to full diligence. A group running 48% overhead, for example, signals an immature management structure and uncontrolled location-level costs, both of which compress the multiple offered. The effect is material, and a 5-point overhead reduction on a group generating $10 million in collections adds $500,000 to normalized EBITDA.
Hitting the 30% benchmark typically requires centralized billing, group purchasing contracts, and a management fee structure that captures the true cost of support services. That work takes years to build, which is why the 5+ years out stage of the timeline is the right time to start.
What Is The 2-Year Rule For Dental Practice Transitions?
The 2-year rule describes the minimum planning window that gives an owner time to correct problems and increase the sale price before going to market. Having a practice professionally valued two years prior to a desired sale gives an owner time to identify issues and address them before a buyer reviews the numbers.
The corollary also matters. The worst time to get a first valuation is after receiving a letter of intent, when there is no basis for comparison and no time to fix gaps. An owner who receives an LOI without a prior valuation has no anchor, no competitive tension, and limited ability to defend the EBITDA the buyer is pricing against.
The 2-year rule is the minimum window, but it is not the ideal one. Owners who want to improve their outcome can treat 5 years as the standard, which allows time to complete a valuation, act on its findings, and let improvements show up in the financials before going to market. A valuation every three to five years keeps that baseline current.
How Much Does Dental Practice Succession Planning Cost?
A professional, diligence-grade valuation carries a fee, and that distinction often matters in a dental practice sale. A healthcare practice valuation typically ranges from $10,000 to $30,000 depending on the number of locations and ownership structure complexity, with most engagements completing within four to eight weeks.
A “free” valuation usually functions as a lead magnet, a rough number that may not hold up under buyer scrutiny. When a buyer’s quality-of-earnings team, the analysts a DSO or private equity firm hires to verify the seller’s financial claims, pokes holes in an unsupported EBITDA figure, the buyer often lowers the offer after the LOI, when the seller has already invested months of time and has limited leverage.
McLerran & Associates builds a CPA-led EBITDA analysis that is diligence-grade work done up front. Every add-back, a discretionary, personal, or non-recurring expense that is added back to net income to show true profitability, is documented and defensible before the practice goes to market. On DSO deals, McLerran provides quality-of-earnings defense through diligence, defending the EBITDA it underwrote when the buyer’s team challenges it and reminding buyers that other vetted bidders are waiting if they attempt to trade the deal down.
What Breaks A Dental Practice Succession Plan?
Most discussions of dental practice succession planning focus on checklists. In practice, a small set of failure modes tends to derail transitions, and owners benefit from addressing these risks early.
Associate Mobility
An associate who leaves before vesting can collapse an internal buy-in or eliminate the buyer a doctor-to-doctor seller expected to rely on. Associate development should begin before hiring, with defined success benchmarks at 90 days, six months, and one year, assigned mentoring responsibility, measurable performance criteria, and compensation that rewards longevity rather than short-term output. Retention and vesting structures work best when the succession plan survives an associate departure rather than depending on one person staying.
Owner Dependency
A practice where the owner-dentist personally generates the majority of revenue is structurally harder to sell at full value. Buyers evaluate how much of the revenue remains if the owner steps away, and that assessment influences valuation.
The financial penalty is quantifiable. Groups where a single dentist controls more than 35% of collections can receive a 1x to 2x EBITDA discount from buyers due to provider dependency risk. Conversely, a trained, non-owner management team can add 1x to 3x EBITDA to a group’s valuation. Mitigation usually requires years of deliberate work, including diversifying production, documenting repeatable processes, strengthening leadership capacity, and aligning incentives with stability.
Deal Re-Trading After LOI
A letter of intent (LOI) is a non-binding agreement that outlines proposed deal terms before formal contracts are signed. After an LOI is signed, a buyer’s quality-of-earnings team conducts diligence, and if the seller’s EBITDA was not built on defensible, documented add-backs, the buyer may use that diligence to lower the offer. This process, called re-trading, appears frequently when sellers enter a DSO process without a diligence-grade valuation.
McLerran & Associates reduces re-trading risk by doing the homework before the deal goes out. The CPA-led EBITDA analysis is built to survive scrutiny, and McLerran’s quality-of-earnings defense keeps buyers accountable to the agreed value while reminding them that other vetted bidders remain in the process.
Missing Buy-Sell Triggers
A buy-sell agreement is a legally binding contract between practice co-owners that governs what happens to an owner’s share if a triggering event occurs. A dental partnership buy-sell agreement should address triggering events including death, permanent disability, retirement, voluntary departure, involuntary departure such as loss of dental license, divorce, and bankruptcy.
The disability trigger is the most commonly missing and often the most statistically likely to matter. Many boilerplate buy-sell agreements downloaded from the internet only address death and contain no disability trigger clause at all, even though disability is more likely for dentists and harder to handle without a defined mechanism. J.P. Morgan Private Bank advises that buy-sell agreements be reviewed every two to three years, or after significant business or personal changes.
Frequently Asked Questions
The questions below address practical concerns owner-dentists often raise when they begin planning a transition.
How Long Does A Dental Practice Sale Typically Take To Close?
Most doctor-to-doctor sales close within 6–12 months from decision to close, assuming clean financials and committed financing. DSO and private equity transactions often take longer, commonly 8–18 months, because buyers complete multi-layer due diligence and internal approval steps before funding.
What Happens To My Staff After A DSO Sale?
Most DSO buyers aim to retain clinical staff and front-office teams, since continuity supports revenue and patient experience. Changes usually appear in benefits, reporting structure, and clinical protocols rather than immediate staff reductions, although specifics vary by platform and should be reviewed in the purchase agreement.
How Early Should I Involve My CPA And Attorney?
Owners benefit from involving dental-experienced tax and legal advisors at least 2 years before a planned transition. Early involvement allows time to address entity structure, compensation arrangements, and buy-sell terms before a buyer reviews the practice, which can improve both valuation and after-tax proceeds.
How Do I Reduce Overhead Before A Sale?
Overhead reduction usually starts with a line-by-line review of staffing, supplies, lab costs, and facility expenses against benchmarks such as the 50-40-30 rule. Centralizing purchasing, tightening scheduling, and renegotiating vendor contracts can lower overhead over 12–24 months, and those improvements tend to flow directly into EBITDA and valuation.
Why Work With A Dental-Only Sell-Side Advisor?
A dental-only sell-side advisor focuses on representing practice owners, not buyers, which aligns incentives with the selling dentist’s outcome. Firms that regularly run both doctor-to-doctor and DSO processes can provide a grounded comparison of pathways, help structure competition among vetted buyers, and defend EBITDA through diligence so the agreed value is more likely to hold at closing.
Conclusion: Sequence Your Plan Before The Market Sequences It For You
Dental practice succession planning functions as a risk-management exercise. The plan matters when it survives the issues that often disrupt dental transitions, including associate mobility, owner dependency, deal re-trading after LOI, and missing buy-sell triggers.
McLerran & Associates focuses on dental-only, sell-side work built on a CPA-led, diligence-grade EBITDA analysis and a structured, auction-like process among a vetted pool of qualified buyers. The firm’s track record includes roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, more than 10,000 practices evaluated, over 100 years of collective dental-industry experience, roughly 35 years in business, and a transaction rate of roughly 85–90%.
McLerran & Associates has offices nationwide, including Cleveland (Justin Klingshim), Atlanta (Matt Sutton), Northern Virginia (Andrew Kobylski), Los Angeles (Steven Au), and Phoenix (Brian Carroll, covering the Mountain West). Wherever a practice is located, the firm brings dental-specific depth and a vetted national buyer pool to the table.
Talk to a dental-only sell-side advisor about your exit.
